CBCA 6360
Board: CBCA
Agency: Department of Health and Human Services
Appellant: Avue Technologies Corporation
Date: 2022-01-14
Outcome: dismissed
DISMISSED FOR LACK OF JURISDICTION: January 14, 2022
CBCA 6360, 6627
AVUE TECHNOLOGIES CORPORATION,
Appellant,
v.
DEPARTMENT OF HEALTH AND HUMAN SERVICES,
Respondent in CBCA 6360,
and
GENERAL SERVICES ADMINISTRATION,
Respondent in CBCA 6627.
Andy Liu and Andrew Victor of Nichols Liu LLP, Washington, DC, counsel for
Appellant.
Lucy G. Mac Gabhann and Douglas W. Kornreich, Office of the General Counsel,
Department of Health and Human Services, Baltimore, MD, counsel for Respondent in
CBCA 6360.
Fallyme E. Guerrero and James T. Van Biber, Office of General Counsel, General
Services Administration, Kansas City, MO, counsel for Respondent in CBCA 6627.
Before Board Judges SHERIDAN, OâROURKE, and CHADWICK.
CHADWICK, Board Judge.
CBCA 6360, 6627 2
These consolidated appeals raise a novel issue. The appellant, Avue Technologies
Corporation (Avue), developed and licenses software that another company sells to the
Government under a schedule contract awarded by the General Services Administration
(GSA). The Food and Drug Administration (FDA) acquired a subscription to the software
from the schedule contractor. Avue now seeks damages under Avueâs software license
agreement, which, as discussed below, we may assume is fully incorporated in the prime
contractorâs schedule contract and in FDAâs order from the prime contractor.
The parties briefed cross-motions for summary judgment on entitlement, but we focus
on a jurisdictional issue on which we invited supplemental briefing after the respondent
agencies raised it in their reply. We must decide without benefit of precedent directly on
point whether Avueâs claim that FDA breached the software license is a claim under a
procurement contract within our limited jurisdiction under the Contract Disputes Act (CDA).
We hold that we lack jurisdiction because Avue does not seek relief under a CDA contract.
Background
The Board previously addressed these appeals in Avue Technologies Corp.
v. Department of Health & Human Services, CBCA 6360, 19-1 BCA ¶ 37,375 (denying a
motion to dismiss arguing that âAvue is [only] a subcontractorâ), and Avue Technologies
Corp. v. Department of Health & Human Services, CBCA 6360, et al., 20-1 BCA ¶ 37,503
(denying two motions to dismiss arguing that (1) Avue submitted its claim to the wrong
agency, and (2) Avue had no GSA contract and â[n]ever dealt directly with GSAâ). We
focus here on the background relevant to the current jurisdictional issue and rely on
undisputed facts propounded by Avue to support its merits motion. See Board Rule 8(f)(1),
(2) (48 CFR 6101.8(f)(1), (2) (2020)).
Avue developed a software âplatformâ that allows government agencies âto automate
federal job classificationâ by interacting with a database. Access to Avueâs software, called
Avue Digital Services (ADS), is sold commercially for a fixed annual subscription. Avue
does not sell subscriptions to the Government directly. Rather, Carahsoft Technology Corp.
(Carahsoft) is an authorized reseller of ADS subscriptions under Carahsoftâs Federal Supply
Schedule (FSS) contract with GSA.
Carahsoft and GSA added ADS to Carahsoftâs existing FSS contract by modification
in May 2012. Box 14 of the modification form states in part, âGSA approved EULA [end
user license agreement] rider are [sic] hereby incorporated into this contract.â The context
indicates that the âEULA riderâ described as being âincorporatedâ is what Avue calls its
master subscription agreement (MSA). The attachments to the 2012 modification include
an unsigned, undated template version of Avueâs MSA (with the words âCLIENT NAMEâ
CBCA 6360, 6627 3
on the title page where the subscriberâs name would be), which Carahsoft had forwarded to
GSA earlier in May 2012. As noted below, the MSA refers to itself as a âstandard
commercial licenseâ for software services and contains terms purporting to bind agency
subscribers. The respondent agencies decline to admit that the Avue MSA was
âincorporatedâ in the FSS contract or in an FDA order, and they emphasize that the MSA in
the modification file is unsigned. They identify no document other than the MSA, however,
that could be the end user license agreement that the modification says it incorporates.
Cf.